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Preoperative Antiviral Therapy and Microvascular Invasion in Hepatitis B 
Virus-Related Hepatocellular Carcinoma: A Meta-Analysis 
Abstract 
Microvascular invasion (MVI) is an important predictor of metastatic tumor 
recurrence and is associated with adverse outcomes and poor prognosis in 
Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients. The
association between varying regimens of anti-viral drugs with the incidence of 
MVI in HBV-related HCC has been demonstrated, however, no meta-analysis 
of the available data has been conducted. Therefore, the current study sought to 
evaluation the association of preoperative antiviral therapy with incidence of 
microvascular invasion in HCC hepatitis virus patients. A systematic search of
the literature was performed in MEDLINE/PubMed, Web of Science (WoS), 
and Scopus, up to January 2020. A random-effects model was used to estimate 
pooled odds ratios (ORs). Overall, six studies, with 4,988 patients, met our 
inclusion criteria. The pooled OR of MVI in the patients who had preoperative 
antiviral therapy versus the patients who did not have antiviral therapy was; OR: 
0.60, 95% Confidence Interval (CI): 0.49-0.73; I2=25%. In this study, a 
significant reduction in the OR of MVI was evident in patients who had anti-
viral therapy. 
Keywords: Anti-viral therapy; Hepatitis B; Hepatocellular Carcinoma;
microvascular invasion 
1. Introduction 
Hepatocellular carcinoma (HCC) is, reportedly, the fifth most prevalent cancer, 
and one of the largest contributors to cancer-related mortality, globally 
(McGlynn and London, 2011; Rahmani et al., 2020). The incidence of HCC is 
heterogenous and studies have estimated the age-standardized incidence rates 
per 100,000 people was the highest in Egypt (32.2), Gambia (23.9), Eastern 
Asia (17.7), and South-East Asia (13.3) (Yang et al., 2019).
Potential curative treatments consist of partial hepatectomy or liver 
transplantation (Bruix et al., 2014; Kachare et al., 2015; Wang et al., 2020);
however, surgical outcomes and long-term prognosis are poor, primarily 
attributed to high rates of tumour recurrence (Poon et al., 2000). Early 
recurrence of HCC, characterised by recurrence <2 y post-surgical intervention,
is attributable to over 60% of HCC recurrence (Wu et al., 2009), and 
interestingly, early recurrence is reportedly related to the presence of 
microvascular invasion (MVI) (Zhang et al., 2018), which represents a
histopathological feature of microscopic metastasis (Rodriguez-Peralvarez et 
al., 2013; Yang et al., 2012b). Indeed, empirical data suggests a significant 
association between hepatitis virus-related HCC and MVI (Bui-Nguyen et al., 
2010; Ryu et al., 2008). In addition, it has been speculated that a hepatitis-
related virus might augment angiogenic processes and disrupt the immune 
responses against tumour cells escaped from the primary tumour-site, thereby 
resulting in vascular metastasis (Yang et al., 2012a). Microvascular invasion has 
been repeatedly established as an independent risk factor for early HCC 
recurrence following surgical treatment, and it has been reported that the 
recurrence-free survival rates are significantly lower in patients with, versus 
without, MVI, 32.7 vs. 75.9%, respectively (Sumie et al., 2014).
Problematically, patients with hepatitis-related HCC are at an increased risk of 
MVI, as compared to patients with HCC formed of alternative aetiologies 
(Sasaki et al., 2017). Moreover, Lei et al reported that serum levels of hepatitis-
related viruses may influence the extent of MVI (Lidor et al., 2015). The recent 
introduction of novel antiviral treatments that directly target Hepatitis C Virus 
(HCV) replication has yielded decreases in HCC occurrence, and even 
recurrence of HCC in those patients with a past history of liver cancer (Conti et 
al., 2016) 
Although the current evidence base suggests a potential association of 
preoperative antiviral therapy with MVI formation in hepatitis-related HCC;
currently, clinical consensus has been lacking, with no summative assessment 
having been conducted. Thus, the current study sought to evaluate the 
association between preoperative antiviral therapy and incidence of MVI in
HCC hepatitis virus patients.
2. Materials and methods 
2.1. Search in literature 
The present study was conducted in accordance with the Preferred Reporting 
Items in Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher 
et al., 2015). A literature search with Medical Subject Headings (MeSH) and
non-MeSH terms (supplementary Table 1) was performed, without language, 
location, and time restrictions, in PubMed/MEDLINE, Scopus, and Web of 
Science databases, up to January 2020. Furthermore, we scrutinized the 
respective studies reference lists to search for additional papers.
2.2. Inclusion and exclusion criteria 
We included Studies that had a Randomized Controlled Trial (RCT),
retrospective, or prospective design and compared MVI risk in anti-viral 
treatment and non-treatments as an outcome, with appropriate items such as 
hazard ratio, risk ratio, or odds ratio. Other studies, such as review, case report, 
ecological, editorials, and non-human studies were excluded. In instances of 
multi-report studies, the longest follow-up period reported was used for
inclusion in this meta-analysis. Screening of searched studies was performed in 
three steps: 1- removal of duplicate studies; 2- removal of non-related studies 
during title and/or abstract screening; and 3- removal of non-related studies 
during full text evaluation. All steps were performed by two researchers, 
independently. 
2.3. Data extraction and quality assessment 
Data extraction was completed by two authors independently, and in instances 
of disagreement, consensus was achieved through discussion with a senior 
author. In instances of missing data, we contacted the corresponding authors of
included studies. The quality of studies was examined the using the Newcastle-
Ottawa Quality Assessment Scale (NOS), used for observational studies (19). 
2.4. Statistical analysis 
A random effects model was used to pool results (Jackson et al., 2010). The 
group of non-antiviral treatment patients was considered as reference category. 
In order to conduct analysis, the full adjusted model data were extracted from 
primary studies. The I2 statistic (cut point: 50%) and Cochran Q test (P 
heterogeneity (cut-point: 0.10)) were used to evaluate the heterogeneity of
results. Funnel plot, Egger's asymmetry test, Egger's asymmetry plot, and 
Begg's tests, respectively, were conducted to assess potential publication bias,
whilst trim and fill analysis was conducted to adjust results for publication bias. 
The effect of each study, individually, on pooled results was calculated by
sensitivity analysis. STATA 14.0 software used to conduct all statistical 
analyses.
3. Results 
3.1. Literature search 
The literature process is demonstrated in Fig. 1. Accordingly, 201 articles were
retrieved in the initial search. Fifty-two duplicated records were removed, and 
128 articles were excluded following title and abstract screening. Twenty-one 
studies were screened in the full text evaluation, and according to our inclusion 
criteria, 15 irrelevant records were excluded. Finally, six studies met our 
inclusion criteria and were, therefore, included in this meta-analysis (Huang et 
al., 2017; Lei et al., 2016; Li et al., 2018b; Liu et al., 2019; Qu et al., 2019; Wei 
et al., 2017).
3.2. Study characteristics and quality assessment 
Included studies were published from 2016 to 2019, and Table 1 details
characteristics of all included studies. One study had a prospective design (Lei
et al., 2016), and all others had a retrospective design (Huang et al., 2017; Li et 
al., 2018b; Liu et al., 2019; Qu et al., 2019; Wei et al., 2017). In total, of 4,988 
participants, ranging from 349 to 2,362, 1,005 participants had antiviral 
treatment, and 2,069 participants showed MVI. The average age of participants 
was 52.6 years and all studies contained both genders. For quality assessment of 
studies, the NOS tool was used, and two studies showed high quality (Lei et al., 
2016; Li et al., 2018b). Moreover, the quality assessment of studies detailed in
Supplemental Table 2. 
3.3. Meta-analysis results 
Six articles with 4,988 patients reported relevant outcomes. The pooled Odds 
Ratio (OR) (95% Confidence Interval (CI)) of MVI in the patients who had 
preoperative antiviral therapy, versus the patients who did not have preoperative 
antiviral therapy, was OR: 0.60, 95% CI: 0.49-0.73 (Fig. 2). Indeed, HBV-
Related HCC patients who had treatment with antiviral regimes had a 40% 
lower risk of MVI. Our analysis indicated no significant heterogeneity among 
the included studies (P= 0.24, I2=25%). 
3.4. Publication bias and Sensitivity analysis 
Funnel plots and Egger plots showed an asymmetry and indicated publication 
bias among the included studies (Fig. 3A and 3B, respectively). Begg’s and 
Egger’s tests, respectively, confirmed this publication bias (Begg’s P=0.03 and 
Egger’s regression test P=0.02). The ‘trim and fill’ analysis method was used to 
adjust publication bias among results, and its details are provided in 
Supplemental table 3. Furthermore, sensitivity analysis for each of the included 
studies showed no significant differences, beyond the 95% CI limits of 
calculated pooled standard errors (SEM), for the included studies (Fig 4). 
4. Discussion 
Microvascular invasion is regarded as an important predictor of metastatic 
tumour recurrence and is associated with adverse outcomes and poor prognosis 
in HBV-related HCC patients. Concordantly, studies have shown that the HBV-
related HCC patients were more likely to develop MVI than HCC with other 
aetiologies (Omichi et al., 2015; Zhang et al., 2019). A high preoperative HBV 
viral DNA load in these patients was reported to be an independent risk factor 
of MVI. The results from the accumulated data demonstrate an important 
association between the use of preoperative antivirals in HBV-related HCC 
patients and the incidence of MVI formation and early HCC tumour recurrence 
(Akateh et al., 2019; Elshaarawy et al., 2019; Ke et al., 2019). Moreover, HCC 
patients following an antiviral treatment regimen for more than 90 days before 
surgery was associated with reduced incidence of MVI (Li et al., 2018). Indeed, 
this can also influence early tumour recurrence in partial hepatectomy for HBV-
related HCC. 
This study systematically reviewed the published literature of preoperative 
antiviral therapy for HBV-related HCC, and sought to evaluate the association 
on the incidence of MVI. In total, six cohort studies fulfilled our criteria, where 
all the studies included HBV positive HCC patients, used antiviral treatment, 
and showed MVI. Accordingly, the pooled estimates indicated that preoperative 
antiviral therapy offers potential benefits in reducing the risk of MVI in the 
HBV-related HCC patients by 40%. However, there is no conclusive evidence
on the duration of the preoperative antiviral therapy that can optimally benefit in 
reducing the incidence of MVI and HBV-related HCC tumour recurrence. The
length of anti-viral therapy in most of the included studies was 3 months
(Huang et al., 2017; Wei et al., 2017); indeed, findings from Li et al.
demonstrated that antiviral treatment for HBV, for more than 90 days pre-
resection, was associated with a reduced risk of MVI (OR, 0.75, 95%CI: 0.57-
0.99) (Lei et al., 2016). Therefore, it appears that anti-viral treatment after the 
tumour may be more likely to be successful in preventing MVI formation and a
worsening prognosis. 
Some empirical evidence suggests that antiviral treatment can protect against 
tumour recurrence. Indeed, Huang et al. conducted a RCT on patients with 
HCC, highlighting that patients who received antiviral therapy showed reduced 
tumour recurrence and improved survival (Huang et al., 2018). However, 
caution should be taken while treating HCV patients with a history of HBV, as
it is associated with HBV reactivation in patients who are Hepatitis B surface 
antigen-positive (Sanaka et al., 2018). In the present study, HBV-Related HCC
patients who received treatment with antiviral regimes had a 40% lower risk of 
MVI. Interestingly, Li et al highlighted that a high preoperative HBV-Related 
DNA levels were an independent risk factor of MVI (Li et al., 2018a). Indeed, 
the authors further demonstrated that antiviral treatment was associated with 
reduced MVI incidence, but only in instances where treatment commenced 
more 90 days prior to surgery. Taken together, these findings suggest that, with
respect to MVI-positive HCC, anti-viral therapy may be associated with 
improved survival outcomes and prevention of MVI in HBV-related HCC 
patients. 
Strength and limitations 
To the best of our knowledge, this study is the first meta-analysis to have 
evaluated the association of preoperative antiviral therapy with incidence of 
MVI in HBV-related HCC. The low heterogeneity observed between studies 
was a strength of this work, indicating veracity in our findings, and may be of 
use practically. However, the most important limitation of this study was the 
varying type of anti-viral drugs; indeed, most of the included studies did not 
report the effect of different anti-viral drugs separately, so we could not report 
the effect of each anti-viral drug on risk of MVI. In addition, the potential 
impact of immune status vs. MVI in HBV-related HCC patients was not 
considered amongst the included studies. However, it has been noted that during 
chronic HBV infection, adaptive immunity changes from tolerance,
progressively, to immune activation, inactivation, reactivation, and, 
subsequently, exhaustion, which, indeed, may all represent immune pathogenic 
factors for the development of HCC (Chen and Tian, 2019). A further 
consideration that would be pragmatic to investigate is the co-infection of HBV 
and Hepatitis C (HCV), indeed, in this regard, it has been demonstrated that 
although HBV and HCV are independent risk factors of HCC, the combination 
of both infections can additionally modify HCC development (Tsai et al., 1997).
Clearly, it is important that further work is conducted, considering the 
limitations highlighted above, in addition to delineating the differences between 
populations.
5. Conclusion 
In this study, a reduction in the odds of MVI was evident in patients who 
underwent anti-viral therapy. However, all of the studies included in this meta-
analysis were observational, and thus, there is an urgent need for high-quality, 
large scale RCTs, in different populations, to further confirm the veracity of our 
results. 
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